Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
Thursday, May 04, 2023Formosa Pharmaceuticals Inc and AimMax Therapeutics Inc United States announce the submission of a New Drug Application to the United States Food Drug Administration US FDA for APP a novel aqueous nanosuspension formulation of the potent corticoster...
Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.
Thursday, May 04, 2023Neuraxpharm Group Neuraxpharm the leading European specialty pharmaceutical company focused on the treatment of central nervous system CNS disorders announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals SL Laborator...
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
Thursday, May 04, 2023Galmed Pharmaceuticals Ltd reported today the execution of a definitive agreement for a M equity investment in OnKai Inc leading an investment round of M The agreement provides Galmed with a minority but a strategic stake in Onkai Concurrently a stra...
Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer
Wednesday, May 03, 2023Fusion Pharmaceuticals Inc a clinicalstage oncology company focused on developing nextgeneration radiopharmaceuticals as precision medicines today announced the opening of its stateoftheart radiopharmaceutical manufacturing facility The square foot...
CordenPharma Announces Entry into Oligonucleotide API Manufacturing
Tuesday, May 02, 2023Leveraging decades of solidphase peptide manufacturing experience and extensive downstream processing capacity and capabilities CordenPharma is pleased to announce their decision to enter the synthetic Oligonucleotide manufacturing arena in CordenPha...
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
Tuesday, May 02, 2023Aurinia Pharmaceuticals Inc announced that the Swiss Agency for Therapeutic Products Swissmedic has granted marketing authorization of LUPKYNIS voclosporin in combination with a background immunosuppressive therapy to treat adults with active class I...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Monday, April 24, 2023Rhythm Pharmaceuticals Inc a commercialstage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin receptor MCR pathway diseases today announc...
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
Monday, April 24, 2023BioRestorative Therapies Inc a clinical stage company focused on stem cellbased therapies today announced that it has completed enrollment for the safety runin component of its Phase clinical study of BRTX targeting patients suffering from chronic l...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Thursday, April 20, 2023Orphalan SA an international orphan drug development and commercialization company today announces the commercial launch in the US of Cuvrior a new trientine tetrahydrochloride TETAHCl Cuvrior is now available for the treatment of adult patients with...
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
Thursday, April 20, 2023Clearmind Medicine Inc a biotech company focused on discovery and development of novel psychedelicderived therapeutics to solve major undertreated health problems today announced additional preparations to facilitate the commencement of the companys...
